154 related articles for article (PubMed ID: 35818588)
21. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL
Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D
J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950
[TBL] [Abstract][Full Text] [Related]
22.
Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
[TBL] [Abstract][Full Text] [Related]
23. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
24. Molecular Modeling Studies of Anti-Alzheimer Agents by QSAR, Molecular Docking and Molecular Dynamics Simulations Techniques.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Med Chem; 2020; 16(7):903-927. PubMed ID: 31385775
[TBL] [Abstract][Full Text] [Related]
25. 3D-QSAR, ADME-Tox, and molecular docking of semisynthetic triterpene derivatives as antibacterial and insecticide agents.
Daoui O; Mazoir N; Bakhouch M; Salah M; Benharref A; Gonzalez-Coloma A; Elkhattabi S; Yazidi ME; Chtita S
Struct Chem; 2022; 33(4):1063-1084. PubMed ID: 35345415
[TBL] [Abstract][Full Text] [Related]
26. A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease.
Hernández González JE; Eberle RJ; Willbold D; Coronado MA
Front Mol Biosci; 2021; 8():816166. PubMed ID: 35187076
[TBL] [Abstract][Full Text] [Related]
27. Finding potent inhibitors for COVID-19 main protease (M
Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
[TBL] [Abstract][Full Text] [Related]
28. "Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL
Bhowmik D; Sharma RD; Prakash A; Kumar D
J Mol Struct; 2021 Jun; 1233():130094. PubMed ID: 33612858
[TBL] [Abstract][Full Text] [Related]
29. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
30. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
[TBL] [Abstract][Full Text] [Related]
31. In silico investigation of phytoconstituents from Cameroonian medicinal plants towards COVID-19 treatment.
Chtita S; Fouedjou RT; Belaidi S; Djoumbissie LA; Ouassaf M; Qais FA; Bakhouch M; Efendi M; Tok TT; Bouachrine M; Lakhlifi T
Struct Chem; 2022; 33(5):1799-1813. PubMed ID: 35505923
[TBL] [Abstract][Full Text] [Related]
32. Prioritisation of Compounds for 3CL
Jukič M; Škrlj B; Tomšič G; Pleško S; Podlipnik Č; Bren U
Molecules; 2021 May; 26(10):. PubMed ID: 34070140
[TBL] [Abstract][Full Text] [Related]
33. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
[TBL] [Abstract][Full Text] [Related]
34. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL
Vincent S; Arokiyaraj S; Saravanan M; Dhanraj M
Front Mol Biosci; 2020; 7():613401. PubMed ID: 33425994
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CL
Herlah B; Hoivik A; Jamšek L; Valjavec K; Yamamoto N; Hoshino T; Kranjc K; Perdih A
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631364
[TBL] [Abstract][Full Text] [Related]
36. Ligand-based quantitative structural assessments of SARS-CoV-2 3CL
Adhikari N; Banerjee S; Baidya SK; Ghosh B; Jha T
J Mol Struct; 2022 Mar; 1251():132041. PubMed ID: 34866654
[TBL] [Abstract][Full Text] [Related]
37. AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2.
Tang B; He F; Liu D; Fang M; Wu Z; Xu D
bioRxiv; 2020 Mar; ():. PubMed ID: 32511346
[TBL] [Abstract][Full Text] [Related]
38. Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors.
Wu X; Wu S; Chen WH
J Mol Model; 2012 Mar; 18(3):1207-18. PubMed ID: 21695506
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Some Antiviral Natural Products to Fight Against Novel Coronavirus (SARS-CoV-2) Using an
Shah A; Patel V; Parmar B
Comb Chem High Throughput Screen; 2021; 24(8):1271-1280. PubMed ID: 32881661
[TBL] [Abstract][Full Text] [Related]
40. Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL
Jukič M; Janežič D; Bren U
Molecules; 2020 Dec; 25(24):. PubMed ID: 33316996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
